Eisai’s Leqembi deemed too costly for NHS
Though the UK became the first country in Europe to authorize use of Eisai and Biogen’s early Alzheimer’s disease drug,…
All articles by Justine Ra
Justine Ra
Justine Ra is a healthcare reporter for Clinical Trials Arena and Pharmaceutical Technology, focusing coverage on neurology and neurodegenerative diseases. Justine holds a degree in English from The University of Michigan, Ann Arbor.
-
-
Pfizer and BioNTech’s Covid-19/flu combination vaccine falters in Phase III readout
Pfizer and BioNTech have announced that a Phase III trial studying their investigational combination mRNA vaccine for the treatment of…
-
Pfizer touts positive topline data for RSV vaccine Abrysvo
Pfizer has announced positive topline results from a pivotal late-stage study of its respiratory syncytial virus (RSV) vaccine, Abrysvo, in…
-
MSD sets sights on bispecific antibody market with Curon acqusition
In a bid to further diversify its pipeline, Merck & Co (MSD) has announced that it is set to acquire…
-
AAIC 2024: Eisai presents positive long-term data with Leqembi
Eisai has announced that patients undergoing continuous treatment with its anti-amyloid therapy Leqembi (lecanemab) for three years have shown a…
-
AAIC 2024: the evolution of Alzheimer’s clinical trials
As the industry paints an increasingly clearer picture for Alzheimer’s disease pathologies, treatments are becoming more inclusive of non-pharmacological lifestyle…
-
FDA accepts Mesoblast’s latest BLA for paediatric GvHD cell therapy
Mesoblast has announced that the US Food and Drug Administration (FDA) has accepted a resubmitted biologics license application (BLA) for…
-
BMS gains EMA validation for Opdivo/Yervoy combo in liver cancer
Bristol Myers Squibb has announced that the European Medicines Agency (EMA) will begin a review of its application covering the…
-
FDA priority review advances Atara’s tabelecleucel for viral infection
Atara Biotherapeutics has announced that the US Food and Drug Administration (FDA) has awarded a priority review for its biologics…
-
Delix plans further trials with neuroplastogen after positive Phase I data
Delix Therapeutics is planning to initiate two studies to evaluate patients with major depression investigating its lead neuroplastogen candidate, DLX-001,…